Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CRYO CELL INTERNATIONAL INC
Report date May 08, 2017 · Filed August 14, 2017
Jointly reported with CDMJ Nyberg Family Trust
Section 16 reporting ended · disclosed 2017-08-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy trust | 700,000 |
Reported balance
After 2017-05-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-05-08 · Sale · Disposed 146,780 · Balance 700,000 F1: Following the sale of 146,780 shares reported herein, each of the reporting persons ceased to be a ten percent owner of the issuer on May 8, 2017. On July 21, 2017 and July 24, 2017, the reporting persons sold an aggregate of an additional 100,000 shares of the issuer's common stock. F2: These shares are owned directly by the CDMJ Nyberg Family Trust, U/A/D June 9, 2005, a ten percent owner of the issuer, and indirectly by Mary J. Nyberg, as trustee of the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Following the sale of 146,780 shares reported herein, each of the reporting persons ceased to be a ten percent owner of the issuer on May 8, 2017. On July 21, 2017 and July 24, 2017, the reporting persons sold an aggregate of an additional 100,000 shares of the issuer's common stock.
F2: These shares are owned directly by the CDMJ Nyberg Family Trust, U/A/D June 9, 2005, a ten percent owner of the issuer, and indirectly by Mary J. Nyberg, as trustee of the trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2017 Filed Aug 14, 2017 19:47 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | SaleCommon Stock | 146,780 | $5.27 | $773,530.60 |
DisclosureSEC source: 0000899243-17-020230 · doc4.xml · nonDerivative · entry 1 Nyberg Mary J · CIK 0001700853 · 10% owner CDMJ Nyberg Family Trust · CIK 0001714281 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 700,000 F1 · balance_after: Following the sale of 146,780 shares reported herein, each of the reporting persons ceased to be a ten percent owner of the issuer on May 8, 2017. On July 21, 2017 and July 24, 2017, the reporting persons sold an aggregate of an additional 100,000 shares of the issuer's common stock. F2 · ownership.nature: These shares are owned directly by the CDMJ Nyberg Family Trust, U/A/D June 9, 2005, a ten percent owner of the issuer, and indirectly by Mary J. Nyberg, as trustee of the trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.